Compare PPG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPG | RPRX |
|---|---|---|
| Founded | 1883 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 22.0B |
| IPO Year | 2014 | 2020 |
| Metric | PPG | RPRX |
|---|---|---|
| Price | $117.70 | $55.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $124.25 | $51.40 |
| AVG Volume (30 Days) | 1.5M | ★ 3.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.71% | 1.90% |
| EPS Growth | ★ 46.11 | N/A |
| EPS | ★ 1.70 | 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $4.42 | $38.63 |
| Revenue Next Year | $3.03 | $4.73 |
| P/E Ratio | ★ $69.95 | $79.96 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $93.39 | $34.63 |
| 52 Week High | $133.43 | $56.50 |
| Indicator | PPG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 58.31 |
| Support Level | $100.89 | $35.33 |
| Resistance Level | $118.37 | $56.50 |
| Average True Range (ATR) | 3.12 | 1.40 |
| MACD | 0.18 | -0.27 |
| Stochastic Oscillator | 51.11 | 76.73 |
PPG is the world's second-largest producer of paints and coatings. PPG's products are sold to a wide variety of end users, including industrial segments such as automotive, aerospace, and protective and marine, as well as paint contractors and do-it-yourself customers. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.